Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma

Immutep (NASDAQ:IMMP, ASX:IMM) has announced data related to its Part B ongoing Phase I TACTI-mel clinical study of its lead...

Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer

Immutep (ASX:IMM,NASDAQ:IMMP) has announced it has received the grant of a new patent called “Use of Recombinant LAG-3 on the...